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Introduction: Hepatocellular adenomas (HCAs), with a risk of malignant transformation into hepatocellular carcinoma
(HCC), classically develop in young women who are taking oral contraceptives. It is now clear that HCAs may also
occur in men. However, it is rarely reported that HCAs with malignant transformation occur in male patients with
non-cirrhotic livers. This study aimed to characterize the malignancy of HCAs occurring in male patients.
Methods: All patients with HCAs with malignant transformation who underwent hepatectomy at the Cancer Institute
and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College between January 1, 1999 and
December 31, 2011 were enrolled in the study. The clinical characteristics as well as radiologic and pathologic data
were reviewed.
Results: HCAs with malignant transformation were observed in 5 male patients with non-cirrhotic livers, but not in
female patients. The alpha-fetoprotein (AFP) levels were higher in patients with HCAs with malignant transformation
than in patients with HCAs without malignant transformation. The diameters of the tumors with malignant
transformation were larger than 5 cm in 3 cases and smaller than 5 cm in 2 cases. The 5 patients were all alive
without recurrence by the end of the study period. The disease-free survival times of the 5 patients were 26, 48,
69, 69, and 92 months.
Conclusion: Our results indicate that resection would be advised even if the presumptive diagnosis is adenoma
smaller than 5 cm in diameter, especially in male patients.
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Hepatocellular adenomas (HCAs) are uncommon and
essentially benign tumors of the liver. HCAs occur pre-
dominantly, but not exclusively, in young women taking
oral contraceptives [1,2].
The annual incidence of HCAs in long-term contra-
ceptive users is 3–4 per 100,000 [1]. These data were,
however, recorded in the 1970s from a very limited
number of patients and have not been updated since.
HCAs have also been described in association with rare* Correspondence: dr.wujx@hotmail.com
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treatments [3,4].
HCAs in men are rare and usually solitary [5-8]. Pa-
tients with HCAs are often overweight with one or sev-
eral features of the metabolic syndrome. Because of the
risk of malignant transformation into hepatocellular car-
cinoma (HCC), resection of the nodule is recommended
even for nodules smaller than 5 cm [9,10].
HCAs are caused by benign proliferation of hepato-
cytes with high glycogen and fat content, and they lack
normal hepatic architecture. HCAs usually present as
solitary or multiple tumors that may reach up to 30 cm
in diameter [11].
Over the past few decades, several case reports on
HCAs supporting the risk of malignancy were publisheds is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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be transformed into HCC [14-17]. However, the risk of
malignant transformation of HCAs cannot be reliably
quantified yet. Several studies have shown that approxi-
mately 4.2% of patients whose HCAs have been resected
had pathologic evidence of HCC within their HCAs [11].
The risk of malignant transformation is associated with
the subtype of mutated β-catenin and the size of the
HCA [11,23]. A study showed that malignant transform-
ation of HCA is unusual for nodules <5 cm [11]. How-
ever, detailed molecular studies would be required to
prove a direct link between adenoma and carcinoma.
HCCs that developed from HCAs are typically well
differentiated without vascular invasion, perforation of
visceral peritoneum, or satellite nodules. The alpha-
fetoprotein (AFP) level is usually normal and therefore
not diagnostically reliable [24,25]. If tumors are large
(>5 cm) in diameter, the prognosis is relatively good
compared with HCC patients with cirrhosis [25].
In this study, we analyzed the information of HCAs
with malignant transformation, comparing with that of
HCAs without malignant transformation, and aimed to




All patients who were diagnosed with HCA at the Can-
cer Institute and Hospital, Chinese Academy of Medical
Sciences and Peking Union Medical College between
January 1999 and December 2011 and underwent radical
surgical resection were included in this study. Patients
with severe cardiorespiratory, liver failure, renal failure,
or other malignancies at the time of diagnosis were ex-
cluded. The following factors of the patients were
assessed: demographic characteristics (age, sex, alcohol
intake, tobacco use, and weight), laboratory indicators
including hepatits B surface antigen (HBsAg), AFP,
platelet (PLT) count, alanine aminotransferase (ALT), al-












1 Male 40 23.99 + – 35 137
2 Male 46 26.54 – – 31 36
3 Male 51 25.06 – – 15 22
4 Male 43 24.86 + + 22 62
5 Male 50 29.76 – + 45 106
BMI, body mass index; Sm, smoking status; Al, alcohol intake; ALT, alanine aminotra
INR, international normalized ratio of prothrombin time; HBsAg, hepatits B surface a
AFP, alpha-fetoprotein. +, positive; −, negative.bilirubin (TBIL), and international normalized ratio (INR)
of prothrombin time (PT), tumor parameters (tumor size
and number), and operative and perioperative variables
(operation time, blood loss, and blood transfusion). This
study was approved by the Ethics Committee of the Cancer
Hospital, Chinese Academy of Medical Sciences.Treatments
The patients with HCA with malignant transformation
underwent hepatectomy with margins >1 cm: right lobe
irregular hepatectomy or left lateral lobe resection.
None of the patients had received any other therapy for
HCC, either preoperatively or postoperatively (Table 1).
The HCA patients without malignant transformation
received irregular hepatectomy with negative margins.Follow-up
All patients were followed after operation at 3-month in-
tervals for the first year and at 4- to 6-month intervals
thereafter. The follow-up program included serum AFP
assay, liver function test, abdominal ultrasonography,
and chest X-ray examination. Enhanced computed tom-
ography (CT) or magnetic resonance imaging (MRI) was
performed every 6 months for surveillance of recur-
rence. In cases where a suspicious recurrent or meta-
static lesion was detected, MRI or hepatic angiography
was employed to consolidate the diagnosis.Statistical analysis
Statistical analysis was performed by using SPSS 17.0
software. Continuous variables of normal distribution
are presented as mean ± standard deviation (SD) and
compared by using the independent t test. Continuous
variables of non-normal distribution are presented as
medians and interquartile ranges (IQRs) and were com-
pared by using the Mann–Whitney U test. Categorical
variables were compared by using Fisher’s exact test. In





INR HBsAg HBsAb HBcAb AFP
(ng/mL)
18.3 46.3 0.94 – – – 7.56
17.9 43.8 0.99 – + – 4.37
10.5 39.8 0.92 – – – 5.48
12.4 41.7 0.97 – – – 2.24
6.1 40.5 0.89 – + + 3.01
nsferase; GGT, gamma-glutamyl transferase; TBIL, total bilirubin; ALB, albumin;
ntigen; HBsAb, hepatits B surface antibody; HBcAb, hepatits B core antibody;
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Patient characteristics
This study included 5 HCA patients with HCA with ma-
lignant transformation and 17 patients with HCA with-
out malignant transformation. The 5 patients with HCA
with malignant transformation in this study were all
males, aged 40 to 53 years (the median age: 46 years).
The clinical presentations of all 5 cases were not very
specific; most of them had vague abdominal pain. Two
patients had a history of smoking, and 2 had a history of
alcohol intake (Table 1). Hepatitis B virus (HBV) infec-
tion was not found in any of the patients. However,
hepatitis C virus (HCV) infection was found in 1 patient
(Case No. 5). Obesity and metabolic dysregulations (dia-
betes mellitus and hyperlipidemia) were not observed in
any of the patients. The serum AFP levels were all ≤
20 ng/mL. Preoperative biochemical data, including
ALT, GGT, TBIL, ALB, and INR of PT, were not notice-
ably abnormal (Table 1). Of the 5 patients, 3 underwent
right lobe irregular hepatectomy and 2 underwent left lat-
eral lobe resection. No ascites were observed, and all pa-
tients were in Child-Pugh Class A. Case No. 2 had familial
adenomatous polyposis (FAP). The size of the tumors
ranged from 2 to 16 cm (median: 10 cm; mean: 8.10 ±
5.88 cm). Tumors smaller than 5 cm in diameter were
found in 2 patients (Table 2). Preoperative imaging data
were available for all 5 patients: they all underwent CT ex-
aminations, and 2 of them also underwent MRI examina-
tions. Three lesions showed radiographic evidence of
HCC (Figure 1): 2 with suggestive hepatic angiomyoli-
poma (Figure 2) and 1 with suggestive hepatocellular
adenoma.
The 17 HCA patients without malignant transformation
in this study included 7 males and 10 females, aged 27 to
71 years (the median age: 33 years). All the 17 patients
underwent irregular hepatectomy with negative margins.
Compared with the HCA patients, the ratio of males to fe-
males was higher in patients with HCA with malignant
transformation (P = 0.040), and they had higher AFP levels
(P = 0.009) despite being within the normal range. Fur-
thermore, there were no significant differences in other










1 Right lobe 10 Single Irregular hepat
2 Left lobe 2.5 Single Left lateral lobe
3 Left lobe 2 Single Left lateral lobe
4 Right lobe 16 Single Irregular hepat
5 Right lobe 10 Single Irregular hepat
aWithout invasion of the main vascular branches but with microvascular invasion. Hpatients without malignant transformation and the pa-
tients with HCA with malignant transformation (Table 3).
Histological characteristics of HCAs with malignant
transformation
By visual examination, the tumors were soft, round, yel-
low or tan masses and often with areas of necrosis,
hemorrhage, and fibrosis. One specimen showed a yel-
low stellate nodule in the center (Figure 3). The liver
background showed mild macrovesicular steatosis in 1
case and mild portal chronic inflammation in 2 cases.
However, no significant fibrosis was observed in any of
the 5 cases. The histological grades of HCC in the 5
cases of HCAs with malignant transformation were well
differentiated. Microvascular invasion was identified in 1
case, and no angiolymphatic invasion was identified in
any case. As a typical characteristic of HCC, extensive
reticulum loss was observed in all of the carcinomas
compared with the background adenomas that retained
normal reticulin patterns (Figure 4). The surgical re-
section margins were negative in all 5 cases. Immuno-
histochemical staining for CD34 was negative in the
adenomas, whereas it was positive within the cancer-
ous areas in all 5 cases (Figure 5).
Survival
By the end of this study (October 1, 2013), all patients
were alive without recurrence. The median follow-up
duration was 69 months (range: 26–92 months), and the
disease-free survival for the 5 patients with HCA with
malignant transformation was 26–92 months (Table 1).
The 17 patients with HCAs survived without HCA re-
currence or malignant transformation.
Discussion
In this study, HCAs with malignant transformation were
observed in 5 male patients with non-cirrhotic livers but
in none of the female patients. AFP levels are higher in
HCAs with malignant transformation than in HCAs with-
out malignant transformation. The tumor size was smaller
than 5 cm in 2 patients with HCAs with malignant trans-







ectomy No No Well 92
resection No Yesa Well 69
resection No No Well 69
ectomy No No Well 48
ectomy No No Well 26
CAs, hepatocellular adenomas.
Figure 1 Enhanced computed tomography images show a small mass of approximately 2.5 cm in the largest diameter in the left lateral lobe of
the liver. The tumor equidensity in the plain image (A), hyperdensity in the arterial phase (B), and hypodensity in the portal phase (C) and the
equilibrium phase (D).
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were 26, 48, 69, 69, and 92 months.
Malignant transformation of HCAs is very unusual be-
cause most HCAs are resected at the time of diagnosis.
These data might represent an adenoma-carcinoma pro-
gression sequence in hepatocarcinogenesis, similar to
that observed in colon cancer [26]. The following ques-
tions are still being investigated: when HCA develops
into malignancy, which factors influence malignant
transformation, and what the detailed molecular mecha-
nisms for progression from adenoma to carcinoma are.
HCA size, subtype classification, and male gender are
major risk factors for malignant transformation. Obesity,
diabetes, and combining HCA with FAP are possible risk
factors. HBV, HCV, alcohol intake, and tobacco use may
also be risk factors.Figure 2 Magnetic resonance images show a large mass involving the righ
shows low signal intensity on T1-weighted dual-echo images (A and B), and
phase, heterogenous contrast enhancement is noted. E, in the portal venous
F, the enhancement extent of the tumor remains greater than the liver paren
the tumor and non-tumorous liver simultaneously. The liver is non-cirrhotic.Most HCAs that become malignant are larger than
5 cm in diameter. Only 4.4% of the cases of malignant
transformation were reported in tumors smaller than
5 cm in diameter [11]. However, we have observed tu-
mors with diameters smaller than 5 cm in 2 of 5 cases of
HCA, which might be partly because the surgical treat-
ment for HCA is more rigorous in China due to the high
prevalence of liver cancer [27]. Therefore, resection
should be advised even if the presumptive diagnosis is
adenoma with a small tumor, especially in Chinese male
patients.
Based on the advancement of molecular and immuno-
histochemical technologies over the past few years, HCA
diagnosis has dramatically changed with the new classifi-
cation [23,28]. The classification was updated by the
World Health Organization, and 4 additional categoriest hepatic lobe. The mass with thickened tortuous vessels on the edge
slightly long signal intensity on T2-weighted images (C). D, in the arterial
phase, the heterogenous contrast enhancement of the tumor persists.
chyma in the delayed phase. Coral image (G) and sagittal image (H) show
Table 3 Comparison of clinical and pathologic characteristics between HCAs and HCAs with malignant transformation
Variable HCA group (n = 17) HCC group (n = 5) Statistic P value










Yes (BMI≥ 25 kg/m2) 4 3




AFP (ng/mL) 1.90 (1.51, 2.99) 4.37 (2.63, 6.52) U = 9 0.009
ALT (U/L) 22 (13, 27) 31 (18, 40) U = 26 0.195
GGT (U/L) 23 (13, 44) 62 (29, 122) U = 18 0.055
TBIL (μmol/L) 8.7 (5.8, 9.8) 12.4 (8.3, 18.1) U = 22 0.108
ALB (g/L) 41.3 ± 4.1 42.4 ± 2.6 t = 0.571 0.574
PLT (×109/L) 187.2 ± 40.99 227.6 ± 49.04 t = 1.857 0.078
INR 1.00 (0.93, 1.03) 0.94 (0.91, 0.98) U = 27.5 0.238
Number of tumors (cases) 1.000
1 14 5
≥2 3 0
Tumor diameter (cm) 6.5 (3.5, 9.0) 10.0 (2.3, 13.0) U = 37 0.666
HCA group includes HCAs without malignant transformation; HCC group includes HCAs with malignant transformation. Continuous variables of normal distribution
were expressed as mean ± standard deviation and compared by using the independent t test. Continuous variables of non-normal distribution were expressed as
medians with IQRs in parentheses and compared by using the Mann–Whitney U test. Categorical variables were compared by using the Fisher’s exact test.
GGT, gamma-glutamyl transferase; PLT, platelets; INR, international normalized ratio. Other abbreviations as in Table 2.
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vated, β-catenin–activated, inflammatory, and unclassified
[29]. HCAs with mutated β-catenin are more frequently
interpreted as borderline lesions between HCA and HCC,
and are more frequently associated with the development
of unequivocal HCC than other subtypes of HCA
[23,28,30].
Several specific risk factors, such as male hormone ad-
ministration, glycogenosis, familial polyposis, and male
gender, have now been identified [31]. The prevalence of
malignant HCA is 10 times more frequent in males than
in females [11]. A predominance of HCA was not ob-
served in women in China, which could be the result of
the birth control policy in China and the use of oral con-
traceptives in women [27]. According to the birth con-
trol policy that became effective in China since 1980,
oral contraceptives are commonly used by womenbefore they have their first and usually the only child-
birth, and an intrauterine device is then used by most
Chinese women as a routine birth control method after
the birthchild. In addition, estrogen can protect hepato-
cytes from malignant transformation. Finally, the pro-
portion of women with heavy alcohol and tobacco use is
less than that in men [32]. These reasons might partly
explain why women do not show a high prevalence of
HCC.
In our institute, all of the patients with HCAs with
malignant transformation were males. Therefore, the
management of HCA should primarily be based on gen-
der, especially in China.
Malignant transformation of HCA in patients with
FAP has been previously reported [33]. In our studies, 1
patient had FAP. Chronic alcohol abuse is known to be a
major risk factor for HCC. Alcohol ingestion initiates in
Figure 3 The gross specimen shows a well-demarcated mass in the liver measuring 4.5 cm in diameter. There are congestion and hemorrhage in
most of the tumor tissues, and a yellow stellate nodule in the center of the specimen. Uninvolved liver tissues are grossly unremarkable.
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[34]. Tobacco exposure is also a risk factor for HCC.
Simultaneous exposure to alcohol and tobacco is ex-
pected to promote the development of HCC in an addi-
tive and/or synergistic manner. In this study, 1 patientFigure 4 Microscopic findings of hepatocellular adenoma (HCA) with malign
examination, HCA is composed of uniform benign-appearing hepatocytes (A
nuclear to cytoplasmic ratio with nuclear irregularities and plates more than thad alcohol abuse, 1 had tobacco use, and 1 had both.
Although alcohol intake and tobacco use may promote
malignant transformation of HCA, there is no direct evi-
dence to confirm this transformation. Most cases of
HCC are attributable to hepatitis virus–related chronicant transformation (hematoxylin-eosin staining × 100). On microscopic
), and hepatocellular carcinoma (HCC) comprises tumor cells with a high
wo cells in thickness (B).
Figure 5 Immunohistochemical analysis of CD34 in HCA and HCC (immunohistochemical staining × 200). The CD34 expression is negative in
HCA (A), whereas the positive staining of CD34 is strong and diffused in HCC (B).
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HCV. Nevertheless, there were only a few reported cases
where HCC developed from HCA with HBV infection
and none with HCV [35]. However, there was 1 patient
with chronic infection of HCV in our study group. It is
not clear yet whether HBV or HCV is a risk factor for
malignant transformation of HCA. Metabolic syndrome
was also reported as an emerging condition associated
with the malignant transformation of HCA, particularly
in men. However, it is interesting that, besides being
male and 1 patient with FAP, patients in this study did
not have any metabolic disease or a medication history
with steroid hormones. Further investigations are
needed for defining risk factors and molecular pathways
of HCC from HCA.
Our study is a retrospective study performed at a sin-
gle center, and further studies at multiple centers are
needed to confirm our conclusions. We found that AFP
levels were higher in HCAs with malignant transform-
ation than in HCAs, despite being within the normal
range. We are not able to explain this finding and its
value.Conclusions
To summarize, our study suggested that HCCs can arise
from HCAs in male patients without cirrhosis who may
not have any known risk factors for HCC. Therefore,
complete resection is recommended in male patients
even if the presumptive diagnosis is HCA in a small
size.Consent
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